Zentalis Pharmaceuticals Reports Q2 2025 Financial Results

The latest update is out from Zentalis Pharmaceuticals ( (ZNTL) ).

Zentalis Pharmaceuticals announced its second quarter 2025 financial results and operational progress, highlighting the ongoing DENALI Phase 2 trial for azenosertib in Cyclin E1-positive PROC patients, with topline data expected by the end of 2026. The company completed a strategic restructuring to focus on late-stage development of azenosertib, extending its cash runway into late 2027, and reported a decrease in operating expenses compared to the previous year, reflecting its streamlined focus.

The most recent analyst rating on (ZNTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Zentalis Pharmaceuticals stock, see the ZNTL Stock Forecast page.

Spark’s Take on ZNTL Stock

According to Spark, TipRanks’ AI Analyst, ZNTL is a Neutral.

Zentalis Pharmaceuticals faces significant financial hurdles, with consistent losses and negative cash flows. Technical indicators also show weak momentum. However, recent positive clinical developments provide a glimmer of hope for future growth. Despite the financial and technical challenges, the potential of azenosertib in treating aggressive cancers could offer strategic value, albeit with high risk.

To see Spark’s full report on ZNTL stock, click here.

More about Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing azenosertib, a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The company is conducting clinical trials to evaluate azenosertib as a monotherapy and in combination across multiple tumor types, leveraging its expertise to explore additional opportunities beyond PROC.

Average Trading Volume: 946,169

Technical Sentiment Signal: Sell

Current Market Cap: $101.5M

For a thorough assessment of ZNTL stock, go to TipRanks’ Stock Analysis page.